<DOC>
	<DOCNO>NCT01068704</DOCNO>
	<brief_summary>The purpose study determine BMS-690514 + letrozole effective lapatinib + letrozole patient metastatic hormone receptor positive breast cancer develop progressive disease immediately follow adjuvant antiendocrine therapy</brief_summary>
	<brief_title>Efficacy Safety BMS-690514 Combination With Letrozole Treat Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Documented invasive breast cancer Greater 10 % tumor cell positive estrogen receptor and/or progesterone receptor HER2+ HER2 ( Human Epidermal growth factor Receptor ) disease Rapid disease progression despite treatment tamoxifen , anastrozole exemestane ECOG Performance status = 0 1 Prior hormonal therapy metastatic disease Prior hormonal therapy letrozole adjuvant disease Symptomatic brain metastasis Prior treatment tyrosine kinase inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>